Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund

Abstract:
Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.

Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund

Houston, TX | Posted on November 14th, 2011

Leonardo was founded based on the breakthrough multi-stage drug delivery technology of Dr. Mauro Ferrari, President of the Methodist Hospital Research Institute in Houston. The Company's primary technology is based on micron-sized particles of porous silicon that are loaded with a variety of secondary nanoparticles containing a therapeutic agent, such as a drug or small interfering RNA molecule. These silicon particles protect their payload from several key defenses used by the body and many cancers to thwart the effective delivery of therapeutic agents. Fundamental proof of concept was demonstrated last year in a collaborative effort with the University of Texas Health Science Center in Houston and the MD Anderson Medical Center (Cancer Research, 2010. 70(9): p. 3687-3696), with further proof of concept work ongoing.



The Company achieved a major breakthrough with the initial TETF investment by demonstrating a manufacturing process that it believes can be scaled-up economically to produce sufficient particles for human dosing and eventual commercialization. The second tranche of TETF funds will now be used to design, test and validate the commercial manufacturing process and to initiate toxicology testing as a necessary intermediate step on the way to human trials.



"We are excited to receive this second investment from the TETF," said Bruce D. Given, M.D., Chief Executive Officer of Leonardo Biosystems. "Having demonstrated the feasibility of a high volume manufacturing process necessary for commercialization, we are looking forward to moving ahead aggressively with our development program."



About Leonardo's multi-stage system

Leonardo's lead technology consists of fully biodegradable, porous silicon particles smaller than a red blood cell, which can be loaded with a diverse array of secondary nanoparticles such as liposomes, micelles, carbon nanotubes, dendrimers and metallic nanoparticles. In addition to bypassing many of the body's natural defenses that lead to rapid clearance of nanoparticles administered alone, Leonardo's particles can be designed to seek out tumor vasculature and can be tuned to create an intravascular depot, providing sustained release following a single intravenous injection.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead is a leader in delivering small RNAs for gene silencing, and has programs in anti-obesity therapeutics and regenerative medicine.

About Leonardo Biosystems, Inc.

Leonardo Biosystems is a drug delivery company built around technology developed by Dr. Mauro Ferrari, one of the world's best-known nano-science innovators. Leonardo has a multi-stage delivery platform that has been shown in animal models to be highly effective in targeting delivery of siRNA and small molecule drugs. Leonardo is a portfolio company of Arrowhead Research Corporation (NASDAQ: ARWR).

For more information, please click here

Contacts:
Investor Relations Contact:

Brandi Floberg
or Kathy Price
The Piacente Group, Inc.
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New method to reduce uranium concentration in contaminated water March 18th, 2019

Review of the recent advances of 2D nanomaterials in Lit-ion batteries March 15th, 2019

Converting biomass by applying mechanical force Nanoscientists discover new mechanism to cleave cellulose effectively and in an environmentally friendly way March 15th, 2019

Exotic “second sound” phenomenon observed in pencil lead: At relatively balmy temperatures, heat behaves like sound when moving through graphite, study reports March 15th, 2019

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

A Nanobiotechnology Startup from a small town in India attracts the Global Investors January 27th, 2019

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Agrees to Sell Its Institutional Business Units to Euromoney Institutional Investor PLC for $87.3 Million December 6th, 2018

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

180 Degree Capital Corp. to Report Third Quarter 2018 Financial Results on Monday, October 29, 2018 and to Host a Conference Call on Tuesday, October 30, 2018 October 24th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia March 11th, 2019

New optical imaging system could be deployed to find tiny tumors: Near-infrared technology pinpoints fluorescent probes deep within living tissue; may be used to detect cancer earlier March 8th, 2019

Computer-designed vaccine elicits potent antibodies against RSV: The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more; Seattle startup Icosavax will advance related clinical trials March 8th, 2019

CEA-Leti Breakthrough Opens Path to New Vaccine for HIV: Lipidots Platform Strengthens Immune Response to Protein That Is Key to HIV Vaccine; Results Presented in Nature Publishing Group’s npj Vaccines February 27th, 2019

Announcements

New method to reduce uranium concentration in contaminated water March 18th, 2019

Review of the recent advances of 2D nanomaterials in Lit-ion batteries March 15th, 2019

Converting biomass by applying mechanical force Nanoscientists discover new mechanism to cleave cellulose effectively and in an environmentally friendly way March 15th, 2019

Exotic “second sound” phenomenon observed in pencil lead: At relatively balmy temperatures, heat behaves like sound when moving through graphite, study reports March 15th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project